<DOC>
	<DOC>NCT00936871</DOC>
	<brief_summary>This study has been designed to investigate the effect of lersivirine on the QT/QTc interval in order to help establish the safety profile of lersivirine.</brief_summary>
	<brief_title>The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive, (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, normal 12lead ECG and clinical laboratory tests) History of risk factors for QT prolongation or torsades de pointes (eg, organic heart disease, congestive heart failure, hypokalemia, hypomagnesemia, congenital long QT syndrome, myocardial ischemia or infarction). Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 halflives (whichever is longer) prior to the first dose of trial medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>lersivirine QT QTc ECG HIV NNRTI</keyword>
</DOC>